Production of recombinant protein therapeutics in cultivated mammalian cells, Nature Biotechnology, vol.57, issue.11, pp.1393-1398, 2004. ,
DOI : 10.1038/nbt1021
Biopharmaceutical benchmarks 2014, Nature Biotechnology, vol.11, issue.10, pp.992-1000, 2014. ,
DOI : 10.4161/mabs.25864
Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation, Biotechnology and Genetic Engineering Reviews, vol.9, issue.6, pp.147-175, 2012. ,
DOI : 10.5661/bger-28-147
Challenges in Antibody Development against Tn and Sialyl-Tn Antigens, Biomolecules, vol.5, issue.3, pp.1783-1809, 2015. ,
DOI : 10.3390/biom5031783
URL : https://hal.archives-ouvertes.fr/hal-01221583
Transgen??se animale et humanisation des anticorps, m??decine/sciences, vol.25, issue.12, pp.1149-1154, 2009. ,
DOI : 10.1051/medsci/200925121149
Anticorps humanis??s en th??rapeutique, m??decine/sciences, vol.21, issue.12, pp.1054-1062, 2005. ,
DOI : 10.1051/medsci/200521121054
The growth and potential of human antiviral monoclonal antibody therapeutics, Nature Biotechnology, vol.49, issue.12, pp.1421-1434, 2007. ,
DOI : 10.1016/S0022-1759(99)00223-9
Antibody Vectors for Imaging, Seminars in Nuclear Medicine, vol.40, issue.3, pp.167-181, 2010. ,
DOI : 10.1053/j.semnuclmed.2009.12.005
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2853948
Multivalent antibodies: when design surpasses evolution, Trends in Biotechnology, vol.28, issue.7, pp.355-362, 2010. ,
DOI : 10.1016/j.tibtech.2010.03.007
Industrialization of mAb production technology: The bioprocessing industry at a crossroads, mAbs, vol.1, issue.5, pp.443-452, 2009. ,
DOI : 10.4161/mabs.1.5.9448
Available from, pp.43-45 ,
Production of recombinant protein therapeutics in cultivated mammalian cells, Nature Biotechnology, vol.57, issue.11, pp.1393-1398, 2004. ,
DOI : 10.1038/nbt1021
Fed-Batch Cell Culture Process Optimization A Rationally Integrated Approach Available from, BioProcess International [Internet], 2012. ,
Trends in Upstream and Downstream Process Development for Antibody Manufacturing, Bioengineering, vol.1, issue.4, pp.188-212, 2014. ,
DOI : 10.3390/bioengineering1040188
Cell culture processes for monoclonal antibody production, mAbs, vol.26, issue.5, pp.466-479, 2010. ,
DOI : 10.1007/s10616-006-9004-9
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958569
Automated dynamic fed-batch process and media optimization for high productivity cell culture process development, Biotechnology and Bioengineering, vol.55, issue.5, pp.191-205, 2013. ,
DOI : 10.1002/bit.24602
On the pH-optimum of activity and stability of proteins, Proteins: Structure, Function, and Bioinformatics, vol.271, issue.Database issue, pp.2699-2706, 2010. ,
DOI : 10.1002/prot.22786
Animal Cell Technology: From Biopharmaceuticals to Gene Therapy, 2008. ,
The fate of Pluronic F-68 in chondrocytes and CHO cells, Biotechnology and Bioengineering, vol.14, issue.5, pp.975-987, 2008. ,
DOI : 10.1002/bit.21840
Effects of Elevated pCO2 and Osmolality on Growth of CHO Cells and Production of Antibody-Fusion Protein B1: A Case Study, Biotechnology Progress, vol.55, issue.3, pp.70-77, 2005. ,
DOI : 10.1021/bp049815s
Growth behavior of Chinese hamster ovary cells in a compact loop bioreactor. 2. Effects of medium components and waste products, Journal of Biotechnology, vol.15, issue.1-2, pp.113-128, 1990. ,
DOI : 10.1016/0168-1656(90)90055-G
Harvest and Recovery of Monoclonal Antibodies from Large-Scale Mammalian Cell Culture [Internet] Available from: http://www.biopharminternational.com/harvest-and-recovery-monoclonal-antibodies- large-scale-mammalian-cell-culture ,
Prefiltration in Biopharmaceutical Processes In: Filtration and Purification in the Biopharmaceutical Industry Available from, pp.1-219780849379543, 2007. ,
Advances in Primary Recovery: Centrifugation and Membrane Technology, Biotechnology Progress, vol.24, issue.3, pp.488-495, 2008. ,
DOI : 10.1021/bp070414x
Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodies, mAbs, vol.122, issue.5, pp.578-585, 2012. ,
DOI : 10.1016/j.molimm.2010.12.009
Bilan économique des Entreprises du Médicament -édition 2015 ,
Design, Assess and Optimize for Clinical Success [Internet] Available from ,
Quality by design for biopharmaceuticals, Nature Biotechnology, vol.321, issue.1, pp.26-34, 2009. ,
DOI : 10.1038/nbt0109-26
A Systematic Approach for Scale-Down Model Development and Characterization of Commercial Cell Culture Processes, Biotechnology Progress, vol.22, issue.3, pp.696-703, 2006. ,
DOI : 10.1021/bp0504041
Clarification technologies for monoclonal antibody manufacturing processes: Current state and future perspectives, Biotechnology and Bioengineering, vol.6, issue.4, 2015. ,
DOI : 10.1002/bit.25810
Available from: http://www.ich.org/fileadmin/Public_Web_Site, p.91 ,
Scale down models for cell culture [Internet]. 2013 Availa ble from ,